Plain-English translation of NCT07149857 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This Phase 2 trial is testing ciltacabtagene autoleucel, a personalized cell-based therapy designed to treat multiple myeloma, a cancer of plasma cells in the bone marrow. The study involves two groups of patients who will receive slightly different preparation regimens before getting the medication, to see which approach works better and is safer. Researchers want to understand how well this treatment works and what side effects patients experience.
Multiple myeloma is a serious blood cancer, and standard high-dose chemotherapy with stem cell transplant is not suitable for all newly diagnosed patients—especially those who are older, have other health conditions, or simply prefer not to undergo such intensive treatment. This trial is exploring whether this new cell-based therapy can offer an effective alternative that patients can better tolerate.
You likely qualify if…
You likely don't qualify if…
You will first undergo a procedure called apheresis to collect your white blood cells, which will be sent to a lab to be modified into the therapy. You will continue receiving 1–2 more cycles of your current chemotherapy regimen as part of your standard care. Then you will receive a conditioning chemotherapy regimen (either alone or plus , depending on which group you're in) for 3 days, followed by an intravenous infusion of the modified cell therapy. After that, you will enter a long-term follow-up phase beginning around day 113 that continues until the end of the study.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States